Skip to main content
placeholder image

A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.

Journal Article


Abstract


UOW Authors


  •   Clingan, Phillip (external author)

Publication Date


  • 2020

Citation


  • Luke, J. J., Patel, M. R., Hamilton, E. P., Chmielowski, B., Ulahannan, S. V., Kindler, H. L., . . . Blumenschein, G. (2020). A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.. Journal of Clinical Oncology, 38(15_suppl), 3004. doi:10.1200/jco.2020.38.15_suppl.3004

Web Of Science Accession Number


Start Page


  • 3004

End Page


  • 3004

Volume


  • 38

Issue


  • 15_suppl

Place Of Publication


Abstract


UOW Authors


  •   Clingan, Phillip (external author)

Publication Date


  • 2020

Citation


  • Luke, J. J., Patel, M. R., Hamilton, E. P., Chmielowski, B., Ulahannan, S. V., Kindler, H. L., . . . Blumenschein, G. (2020). A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.. Journal of Clinical Oncology, 38(15_suppl), 3004. doi:10.1200/jco.2020.38.15_suppl.3004

Web Of Science Accession Number


Start Page


  • 3004

End Page


  • 3004

Volume


  • 38

Issue


  • 15_suppl

Place Of Publication